<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <nonSort>The </nonSort>
    <title>journey of CAR-T therapy in hematological malignancies</title>
  </titleInfo>
  <name type="personal">
    <namePart>Junru Lu</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Guan Jiang</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <typeOfResource>text</typeOfResource>
  <genre authority="">Review articles.</genre>
  <originInfo>
    <place>
      <placeTerm type="code" authority="marccountry">xx</placeTerm>
    </place>
    <dateIssued encoding="marc">2022</dateIssued>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <extent>1 online resource (1 article).</extent>
  </physicalDescription>
  <abstract>Chimeric antigen receptor T (CAR-T) cells therapy has revolutionized the treatment paradigms for hematological malignancies, with multi-line therapy-refractory patients achieving durable complete remissions (CR) and relatively high objective response rate (ORR). So far, many CAR-T products, such as Kymriah, Yescarta and Tecartus, have been developed and got the unprecedented results. However, some patients may relapse afterwards, driving intense investigations into promoting the development of novel strategies to overcome resistance and mechanisms of relapse. Notable technical progress, such as nanobodies and CRISPR-Case9, has also taken place to ensure CAR-T cell therapy fully satisfies its medical potential. In this review, we outline the basic principles for the development and manufacturing processes of CAR-T cell therapy, summarize the similarities and differences in efficacy of different products as well as their corresponding clinical results, and discuss CAR-T immunotherapy combined with other clinical effects of drug therapy.</abstract>
  <note type="statement of responsibility">Junru Lu; Guan Jiang.</note>
  <note>Publication type: Review article.</note>
  <note>Linked open-access copy: published version.</note>
  <note>Open access; no subscription required for the linked open-access version. Unrestricted online access star</note>
  <note xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution. See the linked licence for the applicable terms. https://creativecommons.org/licenses/by/4.0/</note>
  <note>In English.</note>
  <subject>
    <topic>Hematological malignancies</topic>
  </subject>
  <subject>
    <topic>Targeted Therapy</topic>
  </subject>
  <subject>
    <topic>Combinatorial Therapy</topic>
  </subject>
  <subject>
    <topic>Drug Product</topic>
  </subject>
  <subject>
    <topic>Car-t Cell Therapy</topic>
  </subject>
  <subject>
    <topic>B. Sc. Medical Laboratory Science</topic>
  </subject>
  <subject>
    <topic>UMUN open access collection</topic>
  </subject>
  <subject>
    <topic>hematology</topic>
  </subject>
  <relatedItem type="host">
    <titleInfo>
      <title>Molecular cancer</title>
    </titleInfo>
    <identifier type="issn">1476-4598</identifier>
    <part>
      <text>Vol. 21, no. 1, (2022), pages/article 194</text>
    </part>
  </relatedItem>
  <identifier type="uri">https://europepmc.org/articles/PMC9547409</identifier>
  <location>
    <url displayLabel="Read open-access publication">https://europepmc.org/articles/PMC9547409</url>
  </location>
  <accessCondition type="restrictionOnAccess">Open access; no subscription required for the linked open-access version.</accessCondition>
  <accessCondition type="useAndReproduction">Creative Commons Attribution. See the linked licence for the applicable terms.</accessCondition>
  <recordInfo>
    <recordContentSource authority="marcorg">local</recordContentSource>
    <recordCreationDate encoding="marc">261005</recordCreationDate>
    <recordChangeDate encoding="iso8601">20261005174906.0</recordChangeDate>
    <recordIdentifier source="local">UMUN-OA-20261005-MLS-064</recordIdentifier>
    <languageOfCataloging>
      <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
    </languageOfCataloging>
  </recordInfo>
</mods>
